2nd Cancer Biotech Of The Week Soars In Market Debut
Juno Therapeutics Inc. soared nearly 63 percent in its Nasdaq debut Friday after raising $265 million in an upsized initial public offering, making it the second cancer immunotherapy developer this week...To view the full article, register now.
Already a subscriber? Click here to view full article